RE:Time to Market for H2S Pipeline4 drugs:
1. Otenaproxesul (ATB-346):
Primary Indication:
Post-Operative Pain
Short-term use as analgesic without GI-bleeding or addictive properties.
KPI: Time-to market in Canada/US (then go off-label)
2. ATB-352
Primary Indication:
TBD
3. ATB-429
Primary Indication:
Mild-to-Moderae Inflammatory Bowel Disease
Biological-sparring new oral treatment.
4. ATB-340
Primary Indication:
Cardiovascular protection
Best time for a big player to buy ATE.TO is now.
GLTA
mstrmnd wrote: That's all that matters.
P2b/3a for OA to prove safety and efficacy for chronic use will be time and resource intensive.
P2b/3a for Post-Operative Pain for 10-14-day course of Otenaproxesul at 150 mg PO daily is ready to go with supporting AME data. Post-op mild LTE vs. GI ulcers, no one cares about 3-5x LTE in small subset especially when self-limiting because bigger concern is post-op DVT prophylaxis (particularly orthopedic surgeries) where incremental risk of GI bleeding with NSAIDs + DVT prophylaxis is a far worse outcome, and stopping prophylaxis due to bleeding is even worse.
Fast-track Otenaproxesul as a GI-safe opioid-sparring agent for mild-to-moderate post-operative pain as a preventative strategy for opioid addiction.
Once it's on the market, all subsequent INDs/CTAs will go faster. Overall this is a much better drug developement strategy imho. GLTA.